Plain-English translation of NCT06128551 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing two new medications called and in people with advanced solid cancers that have a specific genetic mutation (KRAS G12C). The trial will evaluate whether these medications work better alone or when combined together, and will help doctors find the safest and most effective doses.
Many people with this type of genetic mutation in their cancer have limited treatment options after their first treatments stop working. This trial exists to see if this new medication approach can help control these hard-to-treat cancers and improve outcomes for patients who have already tried other therapies.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic regularly to receive either one medication or a combination of both, taken by mouth. The study has two phases: first, doctors will test different doses to find the safest amount, and then in the second phase, more patients will receive the selected dose to confirm how well it works. Throughout your participation, you'll have blood tests, imaging scans, and physical exams to monitor how you're responding to treatment.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States